RxDoctor Payments Data

Jason Stansberry, MD

Pulmonary Disease · Orlando, FLNPI 1588832539

Payments from drug & device makers

$8,807in general payments, 2019–2025

Across 77 payments — averaging $114.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$4K
  • Actelion Pharmaceuticals US, Inc.$2K
  • Bayer$2K
  • Merck$271
  • Medtronic$153
  • Vapotherm Inc$147
  • plus $514 from 9 others

What the payments were for

  • Consulting fees$4,65353%
  • Food & beverage$4,00946%
  • Education$1452%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,807 in reported general payments places this provider in the 65th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$49,895
Medicare patients
156
Services billed
597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Orenitram ErTreprostinil Diolamine72$1,058,319
OpsumitMacitentan76$977,717
UptraviSelexipag26$660,598
Tyvaso DpiTreprostinil24$543,059
AdempasRiociguat18$254,591
LetairisAmbrisentan19$240,777
Ambrisentan55$160,126
AdcircaTadalafil18$73,396
Tadalafil77$36,853
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$15,021
Spiriva HandihalerTiotropium Bromide13$13,942
Breo ElliptaFluticasone/Vilanterol28$11,410
SymbicortBudesonide/Formoterol Fumarate20$7,412
Spiriva RespimatTiotropium Bromide14$7,074
Sildenafil Citrate42$4,197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$2,337$1,638,315102 claims
BayerAdempas$1,653$254,59118 claims
United Therapeutics CorporationAdcirca$3,733$73,39618 claims
GSKBreo Ellipta$36$11,41028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →